ALNYLAM PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M |
| Cost of revenue | $677.2M | $306.5M | $268.2M | $140.2M | $115.0M |
| Cash from operations | $524.1M | -$8.3M | $104.2M | -$541.3M | -$641.7M |
| Capital expenditure | $58.7M | $34.3M | $62.2M | $72.1M | $76.4M |
| Free cash flow | $465.4M | -$42.6M | $41.9M | -$613.3M | -$718.1M |
| Total assets | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B |
| Total liabilities | $4.2B | $4.2B | $4.1B | $3.7B | $3.1B |
Shares outstanding 133.5M · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.